NovoCure (NVCR) Tax Provisions (2014 - 2026)

NovoCure (NVCR) has reported Tax Provisions for 13 consecutive years, with $3.2 million the latest figure, recorded in Q2 2026.

• Quarterly Tax Provisions fell 37.87% year-over-year to $3.2 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was -$4.1 million (down 114.27% YoY) and the FY2025 annual result came in at -$23000.0, down 100.06% from the prior year.
• Tax Provisions climbed to $3.2 million in Q2 2026 per NVCR's latest filing, from $1.9 million in the prior quarter.
• Over the last five years, Tax Provisions for NVCR reached as high as $10.7 million in Q4 2024 and fell as low as -$16.5 million in Q4 2025.
• A 5-year average of $3.8 million and a median of $3.8 million in 2023 frame the typical range for Tax Provisions.
• Annual changes were most pronounced in 2024 — Tax Provisions surged 611.4% — and 2025, when it tumbled 253.56%.
• Year by year, Tax Provisions stood at $4.7 million in 2022, then surged by 80.08% to $8.5 million in 2023, then increased by 25.41% to $10.7 million in 2024, then slumped by 253.56% to -$16.5 million in 2025, then surged by 119.48% to $3.2 million in 2026.
• According to Business Quant data, Tax Provisions over the past three periods registered $3.2 million, $1.9 million, and -$16.5 million for Q2 2026, Q1 2026, and Q4 2025 respectively.